[Dantrolene in juvenile spasticity: 3 months of daily observation].
After a clarifying outline on the most recent anatomo-physiopathologic acquisitions about muscular tone and spasticity, the Author presents the results of a prolonged administration (three months) which was daily controlled, in an Institute for dyskinetic subjects. At the dose of 1 mg/kg/die during the first week, 2 mg/kg/die during the second week and 3 mg/kg/die during the third and the following ones (total posology pro die divided into 3 post-prandium administrations), Dantrolene was administered to 16 subjects of both sexes, whose average age was 13, who presented marked spasticity sometimes accompanied by dystonia. An evaluation was given on these parameters: 1) spasticity estimated in three degrees according to Morosini, 2) passive articular movement (wideness and easiness of maximum excursion), 3) capability of voluntary decontraction, 4) motoricity of relation (motorial difficulty) and 5) dystonic component if present. As a global results, out of 16 cases, nine improved (56%) and seven (44%) remained unaltered. Since the drug resulted to be inefficacious in all cases with dystonia, the global improvement recorded among "pure spastics" rised to 66% of cases. Neither intolerances nor negative secundary effects were noticed.
D000293:Adolescent; D000367:Age Factors; D002648:Child; D003620:Dantrolene / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006429:Hemiplegia / Q000188:drug therapy*; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use*; D008297:Male; D009128:Muscle Spasticity / Q000188:drug therapy; D010264:Paraplegia / Q000188:drug therapy*; D011782:Quadriplegia / Q000188:drug therapy*
D006827:Hydantoins; D003620:Dantrolene
Il dantrolene nella spasticità giovanile: tre mesi di osservazione quotidiana.